<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03415581</url>
  </required_header>
  <id_info>
    <org_study_id>7547</org_study_id>
    <nct_id>NCT03415581</nct_id>
  </id_info>
  <brief_title>Evaluation of Doxazosin to Alter the Abuse of Oxycodone</brief_title>
  <official_title>Doxazosin: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy, adult men and women, aged 21 to 59 years, who abuse opioids and are physically&#xD;
      dependent on them will be recruited to participate in a study to examine the ability of&#xD;
      doxazosin, an epinephrine receptor blocker, to alter the abuse potential of oxycodone. After&#xD;
      participants complete the screening process, they will be scheduled for inpatient admission&#xD;
      onto our clinical inpatient where they will reside during the 8-week study. During Weeks 1-2,&#xD;
      participants will be transitioned from their normal opioid use regime onto oral morphine&#xD;
      until withdrawal dissipates. At this time participants will also be stabilized on the first&#xD;
      dose of doxazosin (0 or 16 mg/day; active doxazosin will be started at 4 mg and increased by&#xD;
      4 mg every 3 days). During Weeks 3-4, either active or placebo oxycodone will be available&#xD;
      (in random order). Monday-Friday each these drugs will be tested using our sample and choice&#xD;
      self-administration procedure. On Friday, participants will also complete a cue exposure&#xD;
      session during which they will be presented drug cues to determine whether the study&#xD;
      medication affects how participants react to them. To summarize, Weeks 1-2 and 5-6 will be&#xD;
      stabilization weeks (0 or 16 mg doses of doxazosin administered in random order) and Weeks&#xD;
      3-4 and 7-8 will be test weeks under each of the doxazosin maintenance doses. At the&#xD;
      conclusion of the study, participants will be given an exit interview, warnings about&#xD;
      re-initiation of opioid use, and counseling about the different treatment options for Opioid&#xD;
      Use Disorder. Within 1 week after discharge, investigators will assess adverse events using&#xD;
      the a number of clinical assessments. At each weekly visits, investigators will assess&#xD;
      participants' interest in treatment and drug use patterns.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy, adult men and women, aged 21 to 59 years, who abuse opioids and are physically&#xD;
      dependent on them will be recruited to participate in a study to examine the ability of&#xD;
      doxazosin, an alpha-1 adrenergic receptor antagonist, to alter the abuse liability of&#xD;
      oxycodone. After participants complete the screening process, they will be scheduled for&#xD;
      admission onto the General Clinical Research Unit on 5-South where they will reside during an&#xD;
      8-week study . During Weeks 1-2, participants will be stabilized on morphine and the first&#xD;
      dose of doxazosin (0 or 16 mg/day; active doxazosin will be started at 4 mg and increased by&#xD;
      4 mg every 3 days; dosing will occur at 8pm each evening). During the stabilization periods,&#xD;
      participants will be treated for emergent withdrawal symptoms with supplemental medications&#xD;
      until withdrawal symptoms have dissipated.&#xD;
&#xD;
      During Weeks 3-4, either active or placebo oxycodone will be available (order of testing&#xD;
      active or placebo oxycodone will be randomized). During active oxycodone weeks, participants&#xD;
      will receive a sample dose of intransasal (IN) oxycodone (0, 12.5, 25, 50, or 100 mg/70kg)&#xD;
      during morning sessions on Monday-Friday. The sampled reinforcer will be available during&#xD;
      afternoon choice sessions using a modified progressive ratio self-administration procedure.&#xD;
      During placebo oxycodone weeks, participants will receive a sample dose of placebo oxycodone&#xD;
      (0 mg/70kg) during morning sessions on Monday-Thursday followed by afternoon choice sessions.&#xD;
      On Friday, participants will receive 25 mg IN oxycodone during a sample session (the&#xD;
      oxycodone dose on Fri morning will always be active). When self-administering oxycodone,&#xD;
      participants will be instructed to insufflate the entire dose through one or both nostrils&#xD;
      within 5-10 seconds. Following the sample session on Fri, participants will complete a cue&#xD;
      exposure session during which they will be presented with neutral cues followed by drug cues.&#xD;
      This procedure will allow the investigators to determine whether the study medication affects&#xD;
      reactivity to drug-related cues after a period of no oxycodone availability. After the cue&#xD;
      exposure session on Fri, participants will be given the opportunity to self-administer&#xD;
      oxycodone. To summarize, Weeks 1-2 and 5-6 will be stabilization weeks (0 or 16 mg doses of&#xD;
      doxazosin administered in random order) and Weeks 3-4 and 7-8 will be test weeks under each&#xD;
      of the doxazosin maintenance doses. At the conclusion of the study, participants will be&#xD;
      given an exit interview during which the study will be described. Those who are interested in&#xD;
      treatment for their drug use at the end of the study will be offered referrals to studies at&#xD;
      our Substance Treatment and Research Service or other treatment providers. Within 1 week&#xD;
      after discharge, investigators will assess adverse events, pregnancy (using a urine pregnancy&#xD;
      test), general health (complete blood count, blood chemistry, urinalysis, blood pressure,&#xD;
      heart rate, body weight, EKG), and suicide (Columbia Suicide Severity Rating Scale).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated by sponsor due to bad risk/benefit ratio.&#xD;
  </why_stopped>
  <start_date type="Actual">February 12, 2017</start_date>
  <completion_date type="Actual">December 23, 2019</completion_date>
  <primary_completion_date type="Actual">December 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid Self-administration</measure>
    <time_frame>Averaged across the 8-week trial.</time_frame>
    <description>Clinical laboratory task where the participant is asked to choose between drug and money. Shown as the mean percent of drug choices.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Craving</measure>
    <time_frame>Averaged across the 8-week trial.</time_frame>
    <description>Self-reported craving for opioid drugs. Participants are asked to indicate the extent to which they agree with the phrase &quot;I want opioids&quot; on a scale of 0 (Not-at-All) to 100 (Completely).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>Doxazosin (Placebo First)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks, followed by 4-week maintenance on active doxasozin (up to 16mg/day or the highest tolerated dose. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxazosin (Active First)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintenance on a daily dose of oral doxazosin (16 mg, or the highest tolerated dose) for 4-weeks, followed by 4-week maintenance on placebo doxasozin. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Oxycodone</intervention_name>
    <description>Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.</description>
    <arm_group_label>Doxazosin (Active First)</arm_group_label>
    <arm_group_label>Doxazosin (Placebo First)</arm_group_label>
    <other_name>Oxycodone HCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cue Session</intervention_name>
    <description>During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.</description>
    <arm_group_label>Doxazosin (Active First)</arm_group_label>
    <arm_group_label>Doxazosin (Placebo First)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participants must meet all of the following inclusion criteria to be enrolled into the&#xD;
        study:&#xD;
&#xD;
          1. 21-59 years of age. Ascertained by: Self-reported age and/or verification with legal&#xD;
             identification.&#xD;
&#xD;
          2. Diagnostic criteria for Opioid Use Disorder moderate-severe (304.00) as per DSM-V&#xD;
             Ascertained by: Clinical interviews (telephone, psychologist, nurse, physician),&#xD;
             naloxone challenge test/visual evidence of opioid withdrawal.&#xD;
&#xD;
          3. No current or past diagnosis of schizophrenia, schizoaffective disorder, or other&#xD;
             psychotic disorder; bipolar I or bipolar II disorder, other major mood, psychotic, or&#xD;
             anxiety disorder that might interfere with the study. Ascertained by: Clinical&#xD;
             interview with physician or nurse.&#xD;
&#xD;
          4. Physically healthy. Ascertained by: Clinical interview with physician, laboratory&#xD;
             tests (urinalysis, blood chemistry, 12-lead ECG), physical examination, self-reported&#xD;
             medical history.&#xD;
&#xD;
          5. Able to perform study procedures. Ascertained by: Practice session or Clinical&#xD;
             Judgement (Psychologist or Physician)&#xD;
&#xD;
          6. Normal body weight. Ascertained by: Body Mass Index &lt;30.&#xD;
&#xD;
          7. Current or history of intranasal opioid use. Ascertained by: Clinical interviews&#xD;
             (telephone, psychologist, and psychiatric NP, or physician).&#xD;
&#xD;
          8. Current intranasal or intravenous use of opioids in amounts and/or frequencies that&#xD;
             meet or exceed those used in the proposed study (e.g., 3-4 tablets of a prescription&#xD;
             opioid medication per day or 1-2 bags of heroin per day). Ascertained by: Clinical&#xD;
             interviews (telephone, psychologist, psychiatric NP, or physician)&#xD;
&#xD;
          9. If female and using oral contraceptives, must use alternative forms of contraception&#xD;
             as well (e.g. condoms in combination with spermicide). Ascertained by: Clinical&#xD;
             interviews (telephone, psychologist, nurse, physician), physical examination.&#xD;
&#xD;
         10. Has not participated in another opioid laboratory study within the past 3 months.&#xD;
             Ascertained by: Clinical interviews (psychologist physician, or psychiatric NP),&#xD;
             review of laboratory records.&#xD;
&#xD;
        Participants will be excluded from study participation if they meet any of the following&#xD;
        exclusion criteria:&#xD;
&#xD;
          1. Meeting DSM-V criteria for substance use disorder (moderate-severe) on drugs other&#xD;
             than opioids, nicotine or caffeine (must be less than 500 mg caffeine daily).&#xD;
             Ascertained by: Clinical interview with physician or psychiatric NP, urine screen,&#xD;
             observation.&#xD;
&#xD;
          2. Participants requesting treatment. Ascertained by: Self-report during interview.&#xD;
&#xD;
          3. Treatment with any investigational drug during the last 30 days. Ascertained by:&#xD;
             Self-report during interview.&#xD;
&#xD;
          4. Participants on parole or probation. Ascertained by: Self-report during interview,&#xD;
             criminal background check upon admission.&#xD;
&#xD;
          5. Currently pregnant or trying to conceive, or currently lactating. Ascertained by:&#xD;
             Blood pregnancy testing at screening, on admission and (beta hCG), and self-report&#xD;
             during interview and study visits.&#xD;
&#xD;
          6. Current or recent history of significant violent or suicidal behavior and/or&#xD;
             suicidal/homicidal risk. Ascertained by: Clinical interview with a psychiatrist or&#xD;
             psychiatric NP, and C-SSRS, MINI, and Beck Depression Inventory (based on current&#xD;
             state and history).&#xD;
&#xD;
          7. Cannot read or understand the self-report assessment forms unaided, or are so severely&#xD;
             disabled that they cannot comply with the requirements of the study. Ascertained by:&#xD;
             Clinical interview (psychologist, physician, or psychiatric NP), or practice session.&#xD;
&#xD;
          8. Elevated liver function tests (i.e., AST and ALT &gt; 3 times the upper limit of normal&#xD;
             (ULN); bilirubin &gt; 2x ULN; hepatitis B or chronic hepatitis C). Ascertained by:&#xD;
             Laboratory tests.&#xD;
&#xD;
          9. Physical disorders that might make participation hazardous such as AIDS, cancer,&#xD;
             baseline hypotension, orthostatic hypotension or syncope, hypertension (blood pressure&#xD;
             &gt; 140/90), uncontrolled diabetes, pulmonary hypertension or heart disease (please note&#xD;
             that participants will be asked about previous visits to a cardiologist, chest pain,&#xD;
             or strong palpitations; if these exist, they will be referred to a cardiologist and&#xD;
             excluded unless cleared for participation by a cardiologist). Ascertained by: Clinical&#xD;
             interview (psychologist, physician, or psychiatric NP) physical examination, 12-lead&#xD;
             ECG.&#xD;
&#xD;
         10. Current major Axis I psychopathology other than opioid use disorder (e.g., mood&#xD;
             disorder with functional impairment or suicide risk, schizophrenia), that might&#xD;
             interfere with ability to participate in the study. Ascertained by: Clinical&#xD;
             interviews (psychologist, physician, or psychiatric NP).&#xD;
&#xD;
         11. Sensitivity, allergy, or contraindication to opioids, doxazosin, adrenergic&#xD;
             antagonists or agonists, or similar compounds. Ascertained by: Clinical interview&#xD;
             (psychologist, physician, or psychiatric NP).&#xD;
&#xD;
         12. Planning to conceive within 6 months of study participation. Ascertained by: Clinical&#xD;
             interview (psychologist, physician, or psychiatric NP).&#xD;
&#xD;
         13. Use of any prescription, over-the-counter medication that affects CYP3A4 activity are&#xD;
             prohibited for at least 7 days prior to the anticipated study start date; or the use&#xD;
             of phosphodiesterase inhibitors and MAOIs 14 days prior to the study. Ascertained by:&#xD;
             Medical History, Clinical Interview ((psychologist, physician, or psychiatric NP).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra D Comer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYSPI/CUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jermaine Jones</name>
      <address>
        <city>Manhattan</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <results_first_submitted>November 20, 2020</results_first_submitted>
  <results_first_submitted_qc>March 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2021</results_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Sandra D. Comer</investigator_full_name>
    <investigator_title>Research Scientist/Professor of Clinical Neurobiology (In Psychiatry)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03415581/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Doxazosin, Then Active Doxazosin</title>
          <description>Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.&#xD;
Intranasal Oxycodone: Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.&#xD;
Cue Session: During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.</description>
        </group>
        <group group_id="P2">
          <title>Active Doxazosin the Placebo Doxazosin</title>
          <description>Maintenance on a daily dose of oral doxazosin (16 mg) for 4 weeks. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.&#xD;
Intranasal Oxycodone: Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.&#xD;
Cue Session: During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doxazosin (Placebo First)</title>
          <description>Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks followed by active maintenance on doxazasin 16 mg (or the highest tolerated dose) for 4 weeks. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.&#xD;
Intranasal Oxycodone: Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.&#xD;
Cue Session: During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.</description>
        </group>
        <group group_id="B2">
          <title>Doxazosin (Active First)</title>
          <description>Maintenance on a daily dose of oral doxazosin (up to 16 mg, or the highest tolerated dose) for 4 weeks, followed by maintenance on doxazosin 0 mg for 4 weeks. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.&#xD;
Intranasal Oxycodone: Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.&#xD;
Cue Session: During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" spread="10.4"/>
                    <measurement group_id="B2" value="47.7" spread="9.3"/>
                    <measurement group_id="B3" value="47.2" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Opioid Self-administration</title>
        <description>Clinical laboratory task where the participant is asked to choose between drug and money. Shown as the mean percent of drug choices.</description>
        <time_frame>Averaged across the 8-week trial.</time_frame>
        <population>The number of participants analyzed for the measure represents 2 individuals who completed testing under both doxazosin and placebo maintenance conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.&#xD;
Intranasal Oxycodone: Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.&#xD;
Cue Session: During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.</description>
          </group>
          <group group_id="O2">
            <title>Doxazosin</title>
            <description>Maintenance on a daily dose of oral doxazosin (16 mg) for 4 weeks. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.&#xD;
Intranasal Oxycodone: Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.&#xD;
Cue Session: During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Self-administration</title>
          <description>Clinical laboratory task where the participant is asked to choose between drug and money. Shown as the mean percent of drug choices.</description>
          <population>The number of participants analyzed for the measure represents 2 individuals who completed testing under both doxazosin and placebo maintenance conditions.</population>
          <units>Mean percentage of Drug Choices</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxycodone 50 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" spread=".26"/>
                    <measurement group_id="O2" value="46" spread=".03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone 0 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" spread=".92"/>
                    <measurement group_id="O2" value="38" spread=".57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone 12.5 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" spread=".44"/>
                    <measurement group_id="O2" value="47" spread=".16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone 100 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread=".03"/>
                    <measurement group_id="O2" value="44" spread=".21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone 25 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" spread=".07"/>
                    <measurement group_id="O2" value="44" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Craving</title>
        <description>Self-reported craving for opioid drugs. Participants are asked to indicate the extent to which they agree with the phrase &quot;I want opioids&quot; on a scale of 0 (Not-at-All) to 100 (Completely).</description>
        <time_frame>Averaged across the 8-week trial.</time_frame>
        <population>The number of participants analyzed for the measure represents 2 individuals who completed testing under both doxazosin and placebo maintenance conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks, Under placebo maintenance the effects of intranasal oxycodone were assessed.</description>
          </group>
          <group group_id="O2">
            <title>Doxazosin</title>
            <description>Maintenance on a daily dose of oral doxazosin (16 mg, or the highest tolerated dose) for 4-weeks. Under doxazosin maintenance the effects of intranasal oxycodone were assessed.</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Craving</title>
          <description>Self-reported craving for opioid drugs. Participants are asked to indicate the extent to which they agree with the phrase &quot;I want opioids&quot; on a scale of 0 (Not-at-All) to 100 (Completely).</description>
          <population>The number of participants analyzed for the measure represents 2 individuals who completed testing under both doxazosin and placebo maintenance conditions.</population>
          <units>units on a scale (0-100)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oxycodone 50 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="12.6"/>
                    <measurement group_id="O2" value="27.3" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone 0 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="14.1"/>
                    <measurement group_id="O2" value="45.3" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone 12.5 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" spread="14.9"/>
                    <measurement group_id="O2" value="50.6" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone 25 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" spread="13.3"/>
                    <measurement group_id="O2" value="34.9" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone 100 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="11.4"/>
                    <measurement group_id="O2" value="26.1" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs and SAEs were assessed throughout the 8-week study period. Data are presented as a function of the 4-week period under which participants received placebo doxazosin, and the 4-week period during which they received active doxazosin.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Maintenance</title>
          <description>Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Doxazosin Maintenance</title>
          <description>Maintenance on a daily dose of oral doxazosin (16 mg, or the highest tolerated dose) for 4-weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostasis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="13" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bradychardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jermaine Jones PhD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>6467746113</phone>
      <email>jermaine.jones@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

